Market Research Logo

Gastric Cancer - Pipeline Review, H2 2018

Gastric Cancer - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 15, 85, 103, 12, 108, 18 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 5, 1, 10 and 3 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Gastric Cancer - Overview
Gastric Cancer - Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Drug Profiles
Gastric Cancer - Dormant Projects
Gastric Cancer - Discontinued Products
Gastric Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Gastric Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Gastric Cancer - Pipeline by 3SBio Inc, H2 2018
Gastric Cancer - Pipeline by AbbVie Inc, H2 2018
Gastric Cancer - Pipeline by AbGenomics International Inc, H2 2018
Gastric Cancer - Pipeline by Abion Inc, H2 2018
Gastric Cancer - Pipeline by Abpro, H2 2018
Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2018
Gastric Cancer - Pipeline by ADC Therapeutics SA, H2 2018
Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
Gastric Cancer - Pipeline by Alkermes Plc, H2 2018
Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2018
Gastric Cancer - Pipeline by Alteogen Inc, H2 2018
Gastric Cancer - Pipeline by Ambrx Inc, H2 2018
Gastric Cancer - Pipeline by amcure GmbH, H2 2018
Gastric Cancer - Pipeline by Amgen Inc, H2 2018
Gastric Cancer - Pipeline by ANP Technologies Inc, H2 2018
Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H2 2018
Gastric Cancer - Pipeline by Argenx SE, H2 2018
Gastric Cancer - Pipeline by Array BioPharma Inc, H2 2018
Gastric Cancer - Pipeline by Asana BioSciences LLC, H2 2018
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
Gastric Cancer - Pipeline by Astellas Pharma Inc, H2 2018
Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2018
Gastric Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Gastric Cancer - Pipeline by Avipep Pty Ltd, H2 2018
Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018
Gastric Cancer - Pipeline by Bayer AG, H2 2018
Gastric Cancer - Pipeline by BeiGene Ltd, H2 2018
Gastric Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018
Gastric Cancer - Pipeline by Biocon Ltd, H2 2018
Gastric Cancer - Pipeline by Bioleaders Corp, H2 2018
Gastric Cancer - Pipeline by BioLineRx Ltd, H2 2018
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Gastric Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018
Gastric Cancer - Pipeline by Camel-IDS NV, H2 2018
Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2018
Gastric Cancer - Pipeline by CARsgen Therapeutics Ltd, H2 2018
Gastric Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2018
Gastric Cancer - Pipeline by Celgene Corp, H2 2018
List of Figures
Number of Products under Development for Gastric Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report